Scott Daniel Cormack
Director/Board Member at PC-TRiADD
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Martin Gleave | M | 65 |
OncoGenex Technologies, Inc.
 OncoGenex Technologies, Inc. Pharmaceuticals: MajorHealth Technology OncoGenex Technologies, Inc. develops drugs for cancer patients. Its products are being developed to block the production of specific proteins associated with the development of treatment resistance which will increase survival time and improve the quality of life for cancer patients. The company was founded in 2000 and is headquartered in Vancouver, Canada.
OncoGenex Pharmaceuticals, Inc.
 OncoGenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OncoGenex Pharmaceuticals, Inc. is a biopharmaceutical company, which engages develops and commercializes new cancer therapies that address treatment resistance in cancer patients. Its product include custirsen, apatorsen, and OGX-225. The company was founded by Martin E. Gleave and Scott Daniel Cormack in October 1991 and is headquartered in Bothell, WA.
PC-TRiADD
 PC-TRiADD Miscellaneous Commercial ServicesCommercial Services PC-TRiADD is a translational research program. It also offers pharmaceutical and biotech companies, as well as external researchers, integrated translational research services such as drug discovery, preclinical testing, tumour biology and clinical research. The company is headquartered in Vancouver, Canada. | 11 years |
| Stephen Robertson | M | 42 | 10 years | |
| Elaine Allison | F | - |
Novelogics Biotechnology, Inc.
 Novelogics Biotechnology, Inc. BiotechnologyHealth Technology Novelogics Biotechnology, Inc. is a pre-clinical stage biotech company based in Vancouver, Canada, that is developing innovative antibody immunotherapies for cancer using a novel "interceptor" approach. Novelogics aims to revolutionize cancer treatment with its innovative solution that acts as an "interceptor" of unattached immunosuppressive proteins that have the capacity to shut down critical cancer-killing immune cells. The Canadian company is seeking staged investments and/or partnerships to advance its program. The company was founded by Wayne Cheney and Elaine Allison, with Allison serving as CEO since incorporation. | - |
| Wayne Cheney | M | - |
Novelogics Biotechnology, Inc.
Novelogics Biotechnology, Inc. BiotechnologyHealth Technology Novelogics Biotechnology, Inc. is a pre-clinical stage biotech company based in Vancouver, Canada, that is developing innovative antibody immunotherapies for cancer using a novel "interceptor" approach. Novelogics aims to revolutionize cancer treatment with its innovative solution that acts as an "interceptor" of unattached immunosuppressive proteins that have the capacity to shut down critical cancer-killing immune cells. The Canadian company is seeking staged investments and/or partnerships to advance its program. The company was founded by Wayne Cheney and Elaine Allison, with Allison serving as CEO since incorporation. | - |
| Conrad Pinette | M | 83 |
PC-TRiADD
PC-TRiADD Miscellaneous Commercial ServicesCommercial Services PC-TRiADD is a translational research program. It also offers pharmaceutical and biotech companies, as well as external researchers, integrated translational research services such as drug discovery, preclinical testing, tumour biology and clinical research. The company is headquartered in Vancouver, Canada.
Vancouver General Hospital
| - |
| Larry Goldenberg | M | - |
Vancouver General Hospital
PC-TRiADD
PC-TRiADD Miscellaneous Commercial ServicesCommercial Services PC-TRiADD is a translational research program. It also offers pharmaceutical and biotech companies, as well as external researchers, integrated translational research services such as drug discovery, preclinical testing, tumour biology and clinical research. The company is headquartered in Vancouver, Canada. | - |
| Douglas Whitehead | M | 76 |
Vancouver General Hospital
| - |
| David Wishart | M | - |
University of Alberta
| 39 years |
| Dennis Parolin | M | - |
PC-TRiADD
PC-TRiADD Miscellaneous Commercial ServicesCommercial Services PC-TRiADD is a translational research program. It also offers pharmaceutical and biotech companies, as well as external researchers, integrated translational research services such as drug discovery, preclinical testing, tumour biology and clinical research. The company is headquartered in Vancouver, Canada. | - |
| Robert McMaster | M | - |
PC-TRiADD
PC-TRiADD Miscellaneous Commercial ServicesCommercial Services PC-TRiADD is a translational research program. It also offers pharmaceutical and biotech companies, as well as external researchers, integrated translational research services such as drug discovery, preclinical testing, tumour biology and clinical research. The company is headquartered in Vancouver, Canada. | - |
| Graeme Boniface | M | - |
PC-TRiADD
PC-TRiADD Miscellaneous Commercial ServicesCommercial Services PC-TRiADD is a translational research program. It also offers pharmaceutical and biotech companies, as well as external researchers, integrated translational research services such as drug discovery, preclinical testing, tumour biology and clinical research. The company is headquartered in Vancouver, Canada. | - |
| John Blunt | M | - |
PC-TRiADD
PC-TRiADD Miscellaneous Commercial ServicesCommercial Services PC-TRiADD is a translational research program. It also offers pharmaceutical and biotech companies, as well as external researchers, integrated translational research services such as drug discovery, preclinical testing, tumour biology and clinical research. The company is headquartered in Vancouver, Canada. | - |
| Samuel Abraham | M | - |
PC-TRiADD
PC-TRiADD Miscellaneous Commercial ServicesCommercial Services PC-TRiADD is a translational research program. It also offers pharmaceutical and biotech companies, as well as external researchers, integrated translational research services such as drug discovery, preclinical testing, tumour biology and clinical research. The company is headquartered in Vancouver, Canada. | - |
| Shaheen Tejani | F | - |
Vancouver General Hospital
| - |
| Karimah Es Sabar | F | 66 |
PC-TRiADD
PC-TRiADD Miscellaneous Commercial ServicesCommercial Services PC-TRiADD is a translational research program. It also offers pharmaceutical and biotech companies, as well as external researchers, integrated translational research services such as drug discovery, preclinical testing, tumour biology and clinical research. The company is headquartered in Vancouver, Canada. | - |
| Michael Richard Crane | M | 82 |
Vancouver General Hospital
| - |
| Ken Spencer | M | - |
PC-TRiADD
PC-TRiADD Miscellaneous Commercial ServicesCommercial Services PC-TRiADD is a translational research program. It also offers pharmaceutical and biotech companies, as well as external researchers, integrated translational research services such as drug discovery, preclinical testing, tumour biology and clinical research. The company is headquartered in Vancouver, Canada. | - |
| Neil Cashman | M | 72 |
Vancouver General Hospital
| 19 years |
| David Tyrrell | M | - |
University of Alberta
| 42 years |
| Peter M. Brown | M | 81 |
PC-TRiADD
PC-TRiADD Miscellaneous Commercial ServicesCommercial Services PC-TRiADD is a translational research program. It also offers pharmaceutical and biotech companies, as well as external researchers, integrated translational research services such as drug discovery, preclinical testing, tumour biology and clinical research. The company is headquartered in Vancouver, Canada. | - |
| Rod Senft | M | - |
PC-TRiADD
PC-TRiADD Miscellaneous Commercial ServicesCommercial Services PC-TRiADD is a translational research program. It also offers pharmaceutical and biotech companies, as well as external researchers, integrated translational research services such as drug discovery, preclinical testing, tumour biology and clinical research. The company is headquartered in Vancouver, Canada. | - |
| Peter John Gerald Bentley | M | 94 |
Vancouver General Hospital
| - |
| Sue Evans | F | - | 10 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Michelle Burris | F | 58 |
OncoGenex Pharmaceuticals, Inc.
OncoGenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OncoGenex Pharmaceuticals, Inc. is a biopharmaceutical company, which engages develops and commercializes new cancer therapies that address treatment resistance in cancer patients. Its product include custirsen, apatorsen, and OGX-225. The company was founded by Martin E. Gleave and Scott Daniel Cormack in October 1991 and is headquartered in Bothell, WA. | 9 years |
| Cameron Lawrence | M | 44 |
OncoGenex Pharmaceuticals, Inc.
OncoGenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OncoGenex Pharmaceuticals, Inc. is a biopharmaceutical company, which engages develops and commercializes new cancer therapies that address treatment resistance in cancer patients. Its product include custirsen, apatorsen, and OGX-225. The company was founded by Martin E. Gleave and Scott Daniel Cormack in October 1991 and is headquartered in Bothell, WA. | 4 years |
| Jack Goldstein | M | 77 |
OncoGenex Pharmaceuticals, Inc.
OncoGenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OncoGenex Pharmaceuticals, Inc. is a biopharmaceutical company, which engages develops and commercializes new cancer therapies that address treatment resistance in cancer patients. Its product include custirsen, apatorsen, and OGX-225. The company was founded by Martin E. Gleave and Scott Daniel Cormack in October 1991 and is headquartered in Bothell, WA. | 7 years |
| Jerry Wan | M | 42 |
OncoGenex Pharmaceuticals, Inc.
OncoGenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OncoGenex Pharmaceuticals, Inc. is a biopharmaceutical company, which engages develops and commercializes new cancer therapies that address treatment resistance in cancer patients. Its product include custirsen, apatorsen, and OGX-225. The company was founded by Martin E. Gleave and Scott Daniel Cormack in October 1991 and is headquartered in Bothell, WA. | 6 years |
| Stephen W. Zaruby | M | 61 | 3 years | |
| Stephen Charles Anderson | M | 61 |
OncoGenex Pharmaceuticals, Inc.
OncoGenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OncoGenex Pharmaceuticals, Inc. is a biopharmaceutical company, which engages develops and commercializes new cancer therapies that address treatment resistance in cancer patients. Its product include custirsen, apatorsen, and OGX-225. The company was founded by Martin E. Gleave and Scott Daniel Cormack in October 1991 and is headquartered in Bothell, WA.
OncoGenex Technologies, Inc.
OncoGenex Technologies, Inc. Pharmaceuticals: MajorHealth Technology OncoGenex Technologies, Inc. develops drugs for cancer patients. Its products are being developed to block the production of specific proteins associated with the development of treatment resistance which will increase survival time and improve the quality of life for cancer patients. The company was founded in 2000 and is headquartered in Vancouver, Canada. | 2 years |
| Neil James Clendeninn | M | 74 |
OncoGenex Technologies, Inc.
OncoGenex Technologies, Inc. Pharmaceuticals: MajorHealth Technology OncoGenex Technologies, Inc. develops drugs for cancer patients. Its products are being developed to block the production of specific proteins associated with the development of treatment resistance which will increase survival time and improve the quality of life for cancer patients. The company was founded in 2000 and is headquartered in Vancouver, Canada.
OncoGenex Pharmaceuticals, Inc.
OncoGenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OncoGenex Pharmaceuticals, Inc. is a biopharmaceutical company, which engages develops and commercializes new cancer therapies that address treatment resistance in cancer patients. Its product include custirsen, apatorsen, and OGX-225. The company was founded by Martin E. Gleave and Scott Daniel Cormack in October 1991 and is headquartered in Bothell, WA. | 4 years |
| Stephen H. Johnston | M | - |
University of Alberta
| 7 years |
| Donald Boykiw | M | - |
University of Alberta
| 7 years |
| Martin Mattingly | M | 66 |
OncoGenex Pharmaceuticals, Inc.
OncoGenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OncoGenex Pharmaceuticals, Inc. is a biopharmaceutical company, which engages develops and commercializes new cancer therapies that address treatment resistance in cancer patients. Its product include custirsen, apatorsen, and OGX-225. The company was founded by Martin E. Gleave and Scott Daniel Cormack in October 1991 and is headquartered in Bothell, WA. | 7 years |
| Laine M. Woollard | M | - |
University of Alberta
| 7 years |
| Terry Sydoryk | M | - |
University of Alberta
| 8 years |
| Marty Proctor | M | 63 |
University of Alberta
| 5 years |
| Jaime Welch | F | - |
OncoGenex Pharmaceuticals, Inc.
OncoGenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OncoGenex Pharmaceuticals, Inc. is a biopharmaceutical company, which engages develops and commercializes new cancer therapies that address treatment resistance in cancer patients. Its product include custirsen, apatorsen, and OGX-225. The company was founded by Martin E. Gleave and Scott Daniel Cormack in October 1991 and is headquartered in Bothell, WA. | - |
| Mike H. Gilchrist | M | - |
University of Alberta
| 6 years |
| George Chow | M | 62 |
University of Alberta
| 8 years |
| Patricia S. Stewart | M | - |
OncoGenex Pharmaceuticals, Inc.
OncoGenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OncoGenex Pharmaceuticals, Inc. is a biopharmaceutical company, which engages develops and commercializes new cancer therapies that address treatment resistance in cancer patients. Its product include custirsen, apatorsen, and OGX-225. The company was founded by Martin E. Gleave and Scott Daniel Cormack in October 1991 and is headquartered in Bothell, WA. | - |
| Michèle Stanners | F | 66 |
University of Alberta
| 3 years |
| Louis Hugo Francescutti | M | - |
University of Alberta
| 5 years |
| Ha-Cheol Kim | M | 61 | - | |
| Larry Mandt | M | - | 9 years | |
| Michelle Griffin | F | 58 |
OncoGenex Pharmaceuticals, Inc.
OncoGenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OncoGenex Pharmaceuticals, Inc. is a biopharmaceutical company, which engages develops and commercializes new cancer therapies that address treatment resistance in cancer patients. Its product include custirsen, apatorsen, and OGX-225. The company was founded by Martin E. Gleave and Scott Daniel Cormack in October 1991 and is headquartered in Bothell, WA. | 5 years |
| Robert Mccue | M | - |
University of Alberta
| 3 years |
| Jay P. Reid | M | 60 |
University of Alberta
| 7 years |
| Raymond Bower | M | - |
University of Alberta
| 4 years |
| Monica Krieger | M | 75 |
OncoGenex Technologies, Inc.
OncoGenex Technologies, Inc. Pharmaceuticals: MajorHealth Technology OncoGenex Technologies, Inc. develops drugs for cancer patients. Its products are being developed to block the production of specific proteins associated with the development of treatment resistance which will increase survival time and improve the quality of life for cancer patients. The company was founded in 2000 and is headquartered in Vancouver, Canada.
OncoGenex Pharmaceuticals, Inc.
OncoGenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OncoGenex Pharmaceuticals, Inc. is a biopharmaceutical company, which engages develops and commercializes new cancer therapies that address treatment resistance in cancer patients. Its product include custirsen, apatorsen, and OGX-225. The company was founded by Martin E. Gleave and Scott Daniel Cormack in October 1991 and is headquartered in Bothell, WA. | 3 years |
| R. Craig Hoskins | M | - |
University of Alberta
| 6 years |
| Benjamin Rovinski | M | 67 | 6 years | |
| Cindy Jacobs | M | 66 |
OncoGenex Technologies, Inc.
OncoGenex Technologies, Inc. Pharmaceuticals: MajorHealth Technology OncoGenex Technologies, Inc. develops drugs for cancer patients. Its products are being developed to block the production of specific proteins associated with the development of treatment resistance which will increase survival time and improve the quality of life for cancer patients. The company was founded in 2000 and is headquartered in Vancouver, Canada.
OncoGenex Pharmaceuticals, Inc.
OncoGenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OncoGenex Pharmaceuticals, Inc. is a biopharmaceutical company, which engages develops and commercializes new cancer therapies that address treatment resistance in cancer patients. Its product include custirsen, apatorsen, and OGX-225. The company was founded by Martin E. Gleave and Scott Daniel Cormack in October 1991 and is headquartered in Bothell, WA. | 3 years |
| H. Parker | F | 68 |
OncoGenex Pharmaceuticals, Inc.
OncoGenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OncoGenex Pharmaceuticals, Inc. is a biopharmaceutical company, which engages develops and commercializes new cancer therapies that address treatment resistance in cancer patients. Its product include custirsen, apatorsen, and OGX-225. The company was founded by Martin E. Gleave and Scott Daniel Cormack in October 1991 and is headquartered in Bothell, WA. | - |
| Douglas Owen Goss | M | - |
University of Alberta
| 7 years |
| Kevin J. Brown | M | 62 |
University of Alberta
| 6 years |
| David Smith | M | 64 |
OncoGenex Pharmaceuticals, Inc.
OncoGenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OncoGenex Pharmaceuticals, Inc. is a biopharmaceutical company, which engages develops and commercializes new cancer therapies that address treatment resistance in cancer patients. Its product include custirsen, apatorsen, and OGX-225. The company was founded by Martin E. Gleave and Scott Daniel Cormack in October 1991 and is headquartered in Bothell, WA. | - |
| Shong Tak Tam | M | 61 |
University of Alberta
| 8 years |
| Lisa Doig | F | - |
University of Alberta
| 4 years |
| Richard L. Coglon | M | 63 |
University of Alberta
| 4 years |
| Regan Davis | M | 59 |
University of Alberta
| 4 years |
| Doug McMillan | M | - |
University of Alberta
| 4 years |
| Wendy Henkelman | F | 59 |
University of Alberta
| 4 years |
| Michele R. Horne | F | - |
University of Alberta
| 4 years |
| Gerald A. Tywoniuk | M | 62 |
University of Alberta
| 4 years |
| Ian Hill | M | - |
University of Alberta
| 4 years |
| Gregory Francis Kennedy | M | 74 |
University of Alberta
| 4 years |
| Michael Binnion | M | 63 |
University of Alberta
| 4 years |
| Donald Sneddon | M | 61 |
University of Alberta
| 4 years |
| Louis Picco | M | 58 |
University of Alberta
| 4 years |
| Mark Jones | M | 62 |
University of Alberta
| 4 years |
| Lori Walton | F | 64 |
University of Alberta
| 1 years |
| Scott Carter | M | - |
University of Alberta
| 4 years |
| Kwok Hay Wong | M | 75 |
University of Alberta
| 3 years |
| David Constable | M | 62 |
University of Alberta
| 4 years |
| Martin Vydra | M | - |
University of Alberta
| 3 years |
| Doyle Sam | M | - |
University of Alberta
| 4 years |
| Anne Bhanu Chopra | F | 61 |
University of Alberta
| 4 years |
| Kar Piaw Quek | M | 63 |
University of Alberta
| 4 years |
| John Pinsent | M | 63 |
University of Alberta
| 4 years |
| Gordon Robert McCormack | M | 59 |
University of Alberta
| 4 years |
| Gregory J. Hansen | M | 58 |
University of Alberta
| 4 years |
| James McDonald | M | 64 |
University of Alberta
| 4 years |
| Dorothy Harris | F | - |
University of Alberta
| 4 years |
| Tony Bright | M | - |
University of Alberta
| 4 years |
| Allen M. Knight | M | 74 |
University of Alberta
| 4 years |
| Bruce Beynon | M | 60 |
University of Alberta
| 4 years |
| Terry Tucker | M | - |
University of Alberta
| 4 years |
| Daniel A. Roulston | M | - |
University of Alberta
| 4 years |
| Peter Scott | M | - |
University of Alberta
| 4 years |
| Mitch Shier | M | 66 |
University of Alberta
| 3 years |
| James David Pratt | M | - |
University of Alberta
| 4 years |
| David Hall | M | 62 |
University of Alberta
| 4 years |
| Antoinette Boquiren | F | 56 |
University of Alberta
| 4 years |
| Jennifer Koury | F | - |
University of Alberta
| 4 years |
| Gregory F. Juneau | M | 57 |
University of Alberta
| 4 years |
| Lyle Oberg | M | 63 |
University of Alberta
| 4 years |
| Steven J. Mackay | M | - |
University of Alberta
| 4 years |
| Grant W. Draper | M | 59 |
University of Alberta
| 4 years |
| Suzanne Gaboury | F | - |
University of Alberta
| 5 years |
| Man Sing Kwok | M | 68 |
University of Alberta
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Canada | 90 | 90.00% |
| United States | 15 | 15.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Scott Daniel Cormack
- Personal Network
